Function of Cell Surface glycoRNAs Identified

Why It Matters

The discovery positions glycoRNAs as a tunable checkpoint in VEGF‑A driven angiogenesis, offering a novel target for drugs aimed at cancer, retinal disorders, and other vascular pathologies. It also expands the functional repertoire of cell‑surface RNAs, reshaping concepts in developmental biology and immunology.

Key Takeaways

• GlycoRNAs bind VEGF‑A, suppressing pro‑angiogenic signaling.
• Heparan sulfate regulates glycoRNA surface presentation.
• Removal of glycoRNAs enhances vascular formation in 3D models.
• Study links RNA‑glycan interface to angiogenesis control.
• Findings open therapeutic avenues for cancer and vascular disorders.

Pulse Analysis

The concept of glycoRNAs—small non‑coding RNAs covalently linked to glycans—has moved from a biochemical curiosity to a functional cell‑surface entity. First reported by Carolyn Bertozzi’s group five years ago, these molecules have been detected on cancer and immune cells, hinting at a broader physiological role. In a recent Nature article, Ryan Flynn and collaborators at Boston Children’s Hospital delineate how glycoRNAs are trafficked to the plasma membrane and how they interact with extracellular proteins. Their work establishes a concrete biological activity for this RNA‑glycan hybrid. Using a combination of CRISPR screens, multi‑color confocal imaging, and in vivo models, the team identified heparan sulfate (HS) as a key regulator of glycoRNA surface abundance. Genetic disruption of HS biosynthesis reduced glycoRNA display, while re‑introduction restored it, confirming a bidirectional relationship. Crucially, the authors showed that surface glycoRNAs bind the heparin‑binding domain of vascular endothelial growth factor A (VEGF‑A) and blunt its pro‑angiogenic signaling. Zebrafish and murine retinal assays demonstrated that loss of glycoRNAs accelerates vascular sprouting, underscoring their repressive function. These findings reshape our understanding of extracellular signaling by introducing a novel RNA‑based checkpoint on angiogenesis. Because VEGF‑A drives tumor neovascularization and pathological eye disease, glycoRNA‑HS complexes emerge as potential therapeutic targets for anti‑angiogenic strategies. Moreover, the RNA‑glycan interface may influence immune sensing of self versus foreign nucleic acids, opening avenues in autoimmunity and vaccine design. Future work will likely explore glycoRNA diversity across tissues, its regulation in disease states, and how modulating this pathway could complement existing biologics.